Value of Abuse-Deterrent Opioids. For your personal use. Not for further distribution.
|
|
- Eunice Gilmore
- 6 years ago
- Views:
Transcription
1 Value of Abuse-Deterrent Opioids
2 HHS Data Show that Prescription Opioid Abuse Continues To Be a Serious Public Health Issue At least half of all opioid overdose deaths in the United States (US) involve a prescription opioid 1 Overdose deaths involving prescription opioids have quadrupled since 1999 From 1999 to 2014, prescription opioids have been associated with over 165,000 overdose related deaths in the US In 2014 alone: Prescription opioids led to over 14,000 overdose related deaths 1 Nearly 2 million people abused or were dependent on prescription pain relievers 2 Approximately 53% to 81% of people who die from prescription opioid overdoses have a history of pain. 3,4 HHS, US Department of Health and Human Services. 1. CDC Web site. Injury prevention & control: opioid overdose. Updated March 12, Accessed May 23, Data from Wide-ranging Online Data for Epidemiologic Research (WONDER) For your database. personal use. Not for further distribution. 2. SAMHSA. Results From the 2014 National Survey on Drug Use and Health: Summary of National Findings. NSDUH Series H-50, HHS Publication No. (SMA) Rockville, MD: SAMHSA; Paulozzi LJ et al. Addiction. 2009;104(9): Lanier WA et al. Pain Med. 2012;13(12):
3 Diversion of Prescription Pain Relievers: 2015 SAMHSA Data Misusers of Prescription Opioids Obtain the Opioid from Doctors over a Third of the time and over Half of the time from Family or Friends Prescription(s) from More than One Doctor, 1.7% Stolen Prescription(s), 0.7% Prescription(s) from One Doctor, 34.0% Other*, 12.0% From Friend or Relative, 54.0% *Other includes: Drug Dealer/Stranger, Internet, Wrote Fake Prescription, Stole from Doctor s Office/Clinic/Hospital/Pharmacy, and Some Other Way. SAMHSA. Results from the 2015 National Survey on Drug Use and Health: Summary of National Findings. NSDUH Series H-48, HHS Publication No. (SMA) Rockville, MD: SAMHSA; September 2015.
4 Standard of Care Urges Health Care Professionals To Initiate Opioid Risk Mitigation Strategies Intervention Identify at Risk Patients Deter Tampering Monitor Abuse & Diversion Treat Addiction Rescue Therapy Non-pharmacologic Risk-assessment tool Psychiatric assessment PDMP check UDT Treatment agreement Limited prescriptions Pill counts Referral/counseling Recovery program Pharmacologic ADOs Naloxone Antagonist PDMP, Prescription Drug Monitoring Program; UDT, urine drug testing. 1. Dowell D et al. MMWR Recomm Rep. 2016;65(1): Chou R et al. J Pain. J Pain. 2009;10(2): Chou R et al. J Pain. J Pain. 2009;10(2): Webster LR, Fine PG. J Pain. 2010;11(7): Gourlay DL et al. Pain Med. 2005;6(2): Agrof f CE, Kahan M, Sellers EM. J Opioid Manag. 2014; 10(2): Nuckols et al. Ann Intern Med. 2014; 160(1): 38-47
5 Frequently Employed Non-Pharmacologic Strategies Have Potential Limitations that Contribute to the Growing Need for Additional Mitigation Approaches Strategies Intended Use Potential Benefits Potential Limitations Risk Assessment Tools Screen for existing substance abuse, addiction potential, and overall risk for aberrant behavior before opioid therapy is initiated and potentially throughout treatment Identification of patients at high risk for opioid overdose or use disorder Identification of patients that will benefit from increased caution, monitoring, or interventions when risk factors are present. Failure to capture risk associated with: Differing populations, e.g. age and gender Mental and physical comorbidities History of legal issues ORT and SOAPP-R have low sensitivity PDMP Track prescribing and dispensing of controlled prescription drugs, providing critical information regarding a patient s use of these agents, e.g. daily dosage, number of prescriptions, prescriber, pharmacy provider Identify and monitor patients who might be at higher risk for opioid overdose or use disorder Identify and monitor patients that are doctor or pharmacy shopping Identify and monitor patients for higher opioid dosage per day PDMP programs differ in their policies and only contain state-specific data (no crosscommunication): 49 states have authorized PDMP utilization, but only a few States require a PDMP check before prescribing About half of primary care providers (PCP) report utilizing PDMPs UDT/UDS Detection of illegal and prescription drugs, as well as intention/accidental drug overdose; monitoring tools for treatment compliance Identify and monitor patients who might be misusing, abusing, or diverting UDS is easy to use on site PCP knowledge gap on result interpretation. UDT are associated with lag time which slows result turnaround time UDS have low sensitivity and only detect drug classes PDMP, Prescription Drug Monitoring Program; UDT, urine drug testing; HPLC: high-performance liquid chromatography. Operational in 49 states plus Guam *Gas chromotography and mass spectrometry may be used to request identification of specific substances Agroff CE, Kahan M, Sellers EM. J Opioid Manag. 2014; 10(2): Manasco AT et al. Pharmacoepidemiol Drug Saf Apr 8. doi: /pds [Epub ahead of print] Nuckols et al. Ann Intern Med. 2014; 160(1): Rutkow L et al. Health Aff (Millwood). 2015;34(3): Updated March 23, Accessed May 23, Markway EC, Baker SN. Orthopedics Nov;34(11): Accessed May 23, Paulozzi, L.J., Kilbourne, E.M., Desai, H.A., 2011a. Pain Med. 12, Li, J. E. Brady et al. Prescription drug monitoring and drug overdose mortality Injury Epidemiology. 1 (1) pp.; 2014 C. Delcher et al. Abrupt decline in oxycodone-caused mortality after implementation of Florida's Prescription Drug Monitoring Program Drug & Alcohol Dependence. 150 pp. 63-8; Reifler L et al. Pain Medicine. 2012;13(3):355-6.
6 The FDA is changing course on Prescription Opioids from Raising Awareness to Seeking Solutions The FDA has developed a comprehensive action plan with 4 main pillars Be more transparent and open. Improve communication with medical community. Improve the available information about opioids. Focus efforts on approving drugs that have the potential to help mitigate the crisis. Continue to prioritize new abuse-deterrent opioid (ADO) formulations 2 Explore and encourage development of more effective abuse-deterrent features 2 Establish guidelines for development of generic versions of ADOs 1,2 Increase scrutiny of proposed new non-ado formulations 2 Work to improve access to naloxone 1,2 FDA, US Food and Drug Administration. 1. Califf RM. Changing course: a new approach to opioid pain medication at FDA. February 5, Accessed May 23, Califf RM et al. N Engl J Med. 2016;374(15):
7 FDA Considers Development of Abuse-Deterrent Opioids To Be a High Public Health Priority Abuse-deterrent properties are defined as those shown to meaningfully deter abuse, even if they do not fully prevent it Abuse-deterrent technologies to date are intended to make: manipulation (crushing, chewing, dissolving, extracting) of the opioid more difficult, or the effect of the manipulated opioid less attractive or rewarding FDA guidance describes the studies to be conducted to demonstrate a given formulation has abuse-deterrent properties, how studies will be evaluated, and what labeling claims may be approved based on results. FDA remains supportive of ADO development FDA. Guidance for Industry: Abuse-Deterrent Opioids Evaluation and Labeling. Rockville, MD: FDA; Califf, Robert M., Janet Woodcock, and Stephen Ostroff. "A Proactive Response to Prescription Opioid Abuse." New England Journal of Medicine (2016). FDA Guidance Issued April One potentially important step towards the goal of creating safer opioid analgesics has been the development of opioids that are formulated to deter abuse. FDA considers the development of these products a high public health priority. FDA Guidance for Industry: Abuse- Deterrent Opioids Evaluation and Labeling (April 2015)
8 Where to Find Abuse-Deterrence Data and Labeling Refer to prescribing information section 9: DRUG ABUSE AND DEPENDENCE Includes descriptions and data regarding the specific product s abusedeterrent studies (will vary by product) If such information does not appear in a product s labeling under section 9, that product is not an ADO, by FDA standards The pharmacokinetic data demonstrate that crushing [Tradename] results in the simultaneous release and rapid absorption of opioid and antagonist. These data along with the results from oral and intranasal clinical abuse potential studies and a clinical abuse potential study of intravenous opioid and antagonist to simulate crushed [Tradename] indicate that [Tradename] has properties that are expected to deter abuse via the oral, intranasal, and intravenous routes. However, abuse of [Tradename] by these routes is still possible. Example of potential labeling for an ADO with category 2 and 3 data FDA. Guidance for Industry: Abuse-Deterrent Opioids Evaluation and Labeling. Rockville, MD: FDA; 2015.
9 Limited Real-World Data Suggests a Reduction in Frequency of Abuse with Extended-Release (ER) Oxycodone (ADO OxyContin )* Observation Data Source Time Frame Change, % Abuse rates (ICD-9-CM) Drug abuse related poison center exposures Diagnosed addiction rates per 100 person-years of opioid use (ICD-9-CM) Diagnosed addiction rates per 100 person-years of opioid use (ICD-9-CM) Truven Health Analytics medical and pharmacy claims 1 6 months prior, 6 months post -18 (P =.034) to -23 (P <.001) RADARS Poison Center 1 year prior, 2 years post -36 (P <.001) Exposures 2 MarketScan commercial 1 year prior, 3 years post -25 database 3 MarketScan commercial 1 year prior, 1 year post -27 (95% CI, database 4-37% to -16%) Drug diversion rates RADARS Drug Diversion 5 2 years prior, 18 months post -53 (P <.001) Drug price law enforcement RADARS Drug Diversion 5 Time of switch to 1 year post -22 (P =.002) Doctor-shopping rates IMS LRx longitudinal patient data 6 6 months prior, 6 months post -40 Self-reported abuse NAVIPPRO Drug Treatment 7 14 months prior, 20 months post -41 (P <.0001) Self-reported abuse RADARS Opioid Treatment 5.5 years prior, 3 years post Decreased Program 8 (% not reported) ICD-9-CM, International Classification of Diseases, Ninth Revision, Clinical Modification; NAVIPPRO, National Addictions Vigilance Intervention and Prevention Program; RADARS, Researched Abuse, Diversion and Addiction-Related Surveillance System. *Selected sources; other studies have been conducted but are not represented here. Commercially insured and Medicaid patients, respectively; no significant change in abuse rates among Medicare-eligible patients in this study. Rate of diagnosed addiction increased among patients dispensed other opioids. 1. Rossiter LF et al. J Med Econ. 2014;17(4): Coplan PM et al. Pharmacoepidemiol Drug Saf. 2013;22(12): Coplan P, Kadakia A. Poster presented at: College on Problems of Drug Dependence 77th Annual Scientific Meeting; June 13-18, 2015; Phoenix, AZ.. 4. Coplan P, Kadakia A. Pharmacoepidemiol Drug Saf. 2015;24(S1):27. Abstract Sev ertson SG et al. J Pain. 2013;14(10): Chilcoat H et al. J Pain. 2014;15(4, suppl):s10. Abstract Butler SF et al. J Pain. 2013;14(4): Dart RC et al. N Engl J Med. 2015;372(3):
10 Limited Real-World Data Suggests a Reduction in Frequency of Abuse with Extended-Release (ER) Oxycodone (ADO OxyContin )* Observation Data Source Time Frame Change, % Abuse rates (ICD-9-CM) Drug abuse related poison center exposures Diagnosed addiction rates per 100 person-years of opioid use (ICD-9-CM) Diagnosed addiction rates per 100 person-years of opioid use (ICD-9-CM) Truven Health Analytics medical and pharmacy claims 1 6 months prior, 6 months post -18 (P =.034) to -23 (P <.001) RADARS Poison Center 1 year prior, 2 years post -36 (P <.001) Exposures 2 MarketScan commercial 1 year prior, 3 years post -25 database 3 MarketScan commercial 1 year prior, 1 year post -27 (95% CI, database 4-37% to -16%) Drug diversion rates RADARS Drug Diversion 5 2 years prior, 18 months post -53 (P <.001) Drug price law enforcement RADARS Drug Diversion 5 Time of switch to 1 year post -22 (P =.002) Doctor-shopping rates IMS LRx longitudinal patient data 6 6 months prior, 6 months post -40 Self-reported abuse NAVIPPRO Drug Treatment 7 14 months prior, 20 months post -41 (P <.0001) Self-reported abuse RADARS Opioid Treatment 5.5 years prior, 3 years post Decreased Program 8 (% not reported) ICD-9-CM, International Classification of Diseases, Ninth Revision, Clinical Modification; NAVIPPRO, National Addictions Vigilance Intervention and Prevention Program; RADARS, Researched Abuse, Diversion and Addiction-Related Surveillance System. *Selected sources; other studies have been conducted but are not represented here. Commercially insured and Medicaid patients, respectively; no significant change in abuse rates among Medicare-eligible patients in this study. Rate of diagnosed addiction increased among patients dispensed other opioids. 1. Rossiter LF et al. J Med Econ. 2014;17(4): Coplan P, Kadakia A. Pharmacoepidemiol Drug Saf. 2015;24(S1):27. Abstract Coplan PM et al. Pharmacoepidemiol Drug Saf. 2013;22(12): Sev ertson SG et al. J Pain. 2013;14(10): Coplan P, Kadakia A. Poster presented at: College on Problems of Drug 6. Chilcoat H et al. J Pain. 2014;15(4, suppl):s10. Abstract 138. Dependence 77th Annual Scientific Meeting; June 13-18, 2015; Phoenix, AZ. 7. Butler SF et al. J Pain. 2013;14(4): Dart RC et al. N Engl J Med. 2015;372(3):
11 Drug Diversion Decreased Upon Introduction of ADO Oxycodone ER (ADO OxyContin ) - RADARS Introduction of ADO Oxycontin Reported reduction in abuse rates following the reformulation of Oxycodone ER (ADO Oxycontin) do not predict the potential reduction of abuse rates of other abuse deterrent products Severtson et al., J Pain, Vol 14, No 10 (October), 2013: pp
12 Prescribing ER ADOs Instead of ER Non-ADOs Was Associated with a Reduction in Misuse/Abuse and NNH Objective: To estimate the change in health care resource utilization, associated costs, and number needed to harm (NNH) associated with prescribing ER non-ados compared to ADOs in a chronic pain population (N = 10,000) treated for a 12-month period of time. Methods: The reduction of misuse and/or abuse events and associated costs resulting from a physician s decision to prescribe an ER ADO instead of an ER non-ado to chronic pain patients was estimated through a decision model analysis. Key Results: Effect of ER Non-ADO and ADO Formulations on Misuse/Abuse Population* Non-ADOs: Number Needed to Harm ADOs: Misuse/Abuse Events Avoided Commercial Medicare Medicaid Veterans Health Administration Note: Number needed to harm is an epidemiologic measure that in this context indicates the number of patients exposed to an ER non-ado before a misuse and/or abuse-related event can be expected, that would not occur with an ER ADO. ER, extended release. *Range of results by population is due to the variability in abuse rates reported in claims databases for these populations. White AG et al. Presented at: ISPOR 21st Annual International Meeting; May 21-25, 2016; Washington, DC. Poster PSY36.
13 Analysis of Clinical Abuse Potential Study Data and Nonmedical Use: Impact on Healthcare Utilization and Cost A post-hoc analysis of clinical abuse potential studies and nonmedical use data resulted in significant associations between: Reductions in overall drug liking (5-point reduction) Decreased nonmedical use rates (2%-11%) Reduced private payer cost for a morphine ($ million) and oxycodone ($ million) ADF 1 Based on this analysis, a model was developed to determine the medical and economic impact of replacing the non-ado ER opioid market with ADOs This model predicted a 13%-31% reduction in abuse-related medical events and annual medical cost savings of up to $1.3 billion 2 * *Excludes drug costs; total net savings will depend on ADO price relative to non-ados. 1. White AG at al. J Opioid Manag. 2015;11(3): White A et al. J Pain. 2016;17(4, suppl):s41. Abstract 263.
14 Summary: Why ADOs? There is no single solution to the prescription opioid epidemic; it requires a comprehensive strategy Currently implemented interventions (ie, PDMP, UDT, ADO) in addressing opioid abuse are still lacking in effectiveness data and have limitations As a pharmacologic intervention, ADOs have properties that are expected to deter abuse, as established by clinical data reviewed by the FDA Real world data suggests a reduction in frequency of abuse with extended-release (ER) oxycodone ADOs should be considered as part of a multipronged approach to reduce opioid abuse in appropriate patients
Prescription Opioid Abuse: Abuse-Deterrent Opioids as Part of a Multipronged Approach. For Pfizer Use Only
Prescription Opioid Abuse: Abuse-Deterrent Opioids as Part of a Multipronged Approach Table of Contents Chronic Pain and Prescription Opioids Source of Prescription Opioids and Patient Risk Assessment
More informationOpioid Analgesics with Abuse- Deterrent Properties: Current Data and Future Opportunities
1 National Academy of Medicine Session 4 Opioid Analgesics with Abuse- Deterrent Properties: Current Data and Future Opportunities Richard C. Dart, MD, PhD Director, Rocky Mountain Poison and Drug Center
More informationChallenges in Conducting Postmarketing Abuse Investigations
Challenges in Conducting Postmarketing Abuse Investigations Paul Coplan, ScD, MBA Risk Management & Epidemiology Purdue Pharma, L.P. ADF Guidance Meeting Washington DC, October 1, 2013 1 That which we
More informationCategory 4 Can we prove that ADF opioids really are?
Human Abuse Liability & Abuse-Deterrent Formulations Category 4 Can we prove that ADF opioids really are? March 7, 2016 Richard C. Dart, MD, PhD Director, Rocky Mountain Poison and Drug Center Executive
More informationKey points. o Potential for nonmedical use, abuse, and diversion of new products
RADARS System Technical Report # 2012Q2-1 Use of unique recipients of dispensed drug (URDD) in assessing the burden of abuse, misuse, and diversion of prescription opioid products Key points Considering
More informationEffect of Abuse-Deterrent Formulations and IR Opioids on Abuse, Overdose and Death from Rx Opioids
Effect of Abuse-Deterrent Formulations and IR Opioids on Abuse, Overdose and Death from Rx Opioids Richard C. Dart, MD, PhD Executive Director, RADARS System Professor, University of Colorado Competing
More informationA LOOK AT ABUSE-DETERRENT OPIOIDS
JULY 2017 Drugs Under Review ICER s report reviewed evidence on ten abuse-deterrent formulations (ADF) of opioids. Nine of the drugs were extended release (ER) opioids, and one was immediate release (IR).
More informationThe Challenge of Treating Pain
FDA Charge to the Committee: FDA Opioid Action Plan and Incorporating the Broader Public Health Impact into the Formal Risk-Benefit Assessment for Opioids Robert M. Califf, MD Commissioner of Food and
More informationSetting the Stage: Are Abuse-Deterrent Opioids Formulations Ready for Prime Time?
Setting the Stage: Are Abuse-Deterrent Opioids Formulations Ready for Prime Time? Lewis S. Nelson, MD New York University School of Medicine New York City Poison Control Center Opioid Abuse Liability
More informationA National Perspective on the Abuse and Diversion of Prescription Drugs
A National Perspective on the Abuse and Diversion of Prescription Drugs Hilary L. Surratt, Ph.D Steven P. Kurtz, Ph.D. ARSH: Center for Applied Research on Substance Use and Health Disparities Faculty
More informationPRESCRIPTION DRUG ABUSE: THE NATIONAL PERSPECTIVE
PRESCRIPTION DRUG ABUSE: THE NATIONAL PERSPECTIVE September 20, 2013 Association of State and Territorial Health Officials Annual Meeting R. Gil Kerlikowske Director of National Drug Control Policy National
More informationVirtual Mentor American Medical Association Journal of Ethics April 2014, Volume 16, Number 4:
Virtual Mentor American Medical Association Journal of Ethics April 2014, Volume 16, Number 4: 279-283. POLICY FORUM OxyContin, the FDA, and Drug Control Gary M. Reisfield, MD One percent of people will
More informationDan Cohen Forum Chair - Abuse DeterrentCoalition. Abuse Deterrent Formulations of Opioids and the Abuse Deterrent Coalition
Dan Cohen Forum Chair - Abuse DeterrentCoalition Abuse Deterrent Formulations of Opioids and the Abuse Deterrent Coalition Prescription Drug Abuse and Diversion Partnering with Law Enforcement, Anti-Drug
More informationEmergency Department Visits Involving Nonmedical Use of Selected Prescription Drugs --- United States,
Morbidity and Mortality Weekly Report (MMWR) Emergency Department Visits Involving Nonmedical Use of Selected Prescription Drugs --- United States, 2004--2008 Weekly June 18, 2010 / 59(23);705-709 Rates
More informationPrescribing Opioids in the Opioid Epidemic. Scott Woffinden, PA-C Jason Chapman, JD
Prescribing Opioids in the Opioid Epidemic Scott Woffinden, PA-C Jason Chapman, JD What's the Problem? http://www.zdoggmd.com/blank-script-taylor-swift-parody/ What's the Problem? CDC 115 Americans die
More informationAs part of the Opioid Analgesic REMS, all opioid analgesic companies must provide the following:
Introduction FDA s Opioid Analgesic REMS Education Blueprint for Health Care Providers Involved in the Treatment and Monitoring of Patients with Pain (January 2018) Background In July 2012, FDA approved
More informationResponding to the Prescription Opioid and Heroin Crisis: An Epidemic of Addiction
Responding to the Prescription Opioid and Heroin Crisis: An Epidemic of Addiction Andrew Kolodny, MD Co-Director, Opioid Policy Research Collaborative Heller School for Social Policy and Management Brandeis
More informationThe Evolution of Abuse Deterrent Drug Formulations: Testing Effectiveness from the Benchtop to the Real World
The Evolution of Abuse Deterrent Drug Formulations: Testing Effectiveness from the Benchtop to the Real World Richard C. Dart, MD, PhD Director, Rocky Mountain Poison and Drug Center Executive Director,
More informationGOVERNMENT S ROLE IN ADDRESSING PRESCRIPTION DRUG ABUSE
POSITION PAPER GOVERNMENT S ROLE IN ADDRESSING PRESCRIPTION DRUG ABUSE Governments across Canada are concerned about the abuse of prescription drugs, with recent policy discussions focused on mitigating
More informationArticle #2 Prescription Drug Overdose CDC: Centers for Disease Control and Prevention. Understanding the Epidemic
Article #2 Prescription Drug Overdose CDC: Centers for Disease Control and Prevention Understanding the Epidemic When the Prescription Becomes the Problem In a period of nine months, a tiny Kentucky county
More informationPrescription Opioid Policies (22 March 2016)
Prescription Opioid Policies (22 March 2016) Prescription opioid misuse and abuse has become problematic in the United States and internationally in economically developed countries. Increased use of opioids
More informationOPIOID OVERDOSE EPIDEMIC: What Healthcare Providers Need to Know
OPIOID OVERDOSE EPIDEMIC: What Healthcare Providers Need to Know WHAT S NEW UPDATE CUMBERLAND, MD Renata J. Henry, M.Ed. Director, Central East ATTC March 16, 2016 Behavioral Health is Essential to Health
More informationThe STOP Measure. Safe and Transparent Opioid Prescribing to Promote Patient Safety and Reduced Risk of Opioid Misuse FEBRUARY 2018
The STOP Measure Safe and Transparent Opioid Prescribing to Promote Patient Safety and Reduced Risk of Opioid Misuse FEBRUARY 2018 AHIP s Safe, Transparent Opioid Prescribing (STOP) Initiative Methodology
More informationInterventions in Prescription Opioid Abuse Do (or can) Prescription Monitoring Programs Make a Difference?
Interventions in Prescription Opioid Abuse Do (or can) Prescription Monitoring Programs Make a Difference? Richard C. Dart, MD, PhD Executive Director of RADARS System, Denver, Colorado Professor, University
More informationLessons Learned from the US Prescription Opioid Abuse Epidemic
Lessons Learned from the US Prescription Opioid Abuse Epidemic Michelle Lofwall, M.D. University of KY, Dept. of Psychiatry Center on Drug and Alcohol Research October 3, 2012 Outline for today s talk
More informationMedication Misuse and Abuse: A Growing Epidemic
Medication Misuse and Abuse: A Growing Epidemic Colorado Providers Association Professionalizing Prevention June 19, 2015 Mancia Ko, PharmD, MBA Associate Director, Medical Affairs,, Ameritox Assistant
More informationUnderstanding the US Opioid Analgesic Market
Understanding the US Opioid Analgesic Market Key Trends & Market Snapshot December 2017 Purdue Pharma L.P. provided funding and content review for this report. Avalere Health maintained full editorial
More informationPotential Solutions to Epidemic Substance Abuse in US and Europe
Potential Solutions to Epidemic Substance Abuse in US and Europe Richard C. Dart, MD, PhD Director, Rocky Mountain Poison and Drug Center, Denver Health 1 Professor, University of Colorado School of Medicine
More informationDo Pre Marketing Studies Anticipate Post Market Consequences? A Case Study of Reformulated Oxycontin
Do Pre Marketing Studies Anticipate Post Market Consequences? A Case Study of Reformulated Oxycontin Edward M. Sellers MD, PhD, FRCPC, FACP Professor Emeritus, University of Toronto Principal, DL Global
More informationTri-County Region Opioid Trends Clackamas, Multnomah, and Washington, Oregon. Executive Summary
Tri-County Region Opioid Trends Clackamas, Multnomah, and Washington, Oregon 2016 Executive Summary 20.8 million people in the United States have a substance use disorder (not limited to opioids), equivalent
More informationAssessing the Clinical Abuse Potential of Abuse Deterrent Opioid Formulations
Assessing the Clinical Abuse Potential of Abuse Deterrent Opioid Formulations November 16, 2016 Beatrice Setnik, PhD VP, Clinical Pharmacology, Early Phase INC Research Disclosure I am an employee of INC
More informationResponding to the Prescription Opioid and Heroin Crisis: An Epidemic of Addiction
Responding to the Prescription Opioid and Heroin Crisis: An Epidemic of Addiction Andrew Kolodny, MD Co-Director, Opioid Policy Research Collaborative Heller School for Social Policy and Management Brandeis
More informationResponding to the Prescription Opioid and Heroin Crisis: An Epidemic of Addiction
Responding to the Prescription Opioid and Heroin Crisis: An Epidemic of Addiction Andrew Kolodny, MD Co-Director, Opioid Policy Research Collaborative Heller School for Social Policy and Management Brandeis
More informationShawn A. Ryan, MD, MBA Assistant Professor, Dept. of Emergency Medicine, University of Cincinnati Chair of Quality & Patient Safety, Jewish
Shawn A. Ryan, MD, MBA Assistant Professor, Dept. of Emergency Medicine, University of Cincinnati Chair of Quality & Patient Safety, Jewish Hospital-Mercy Health Partners Addiction Specialist, BrightView
More informationOpioid Analgesics: Responsible Prescribing in the Midst of an Epidemic
Opioid Analgesics: Responsible Prescribing in the Midst of an Epidemic Lucas Buffaloe, MD Associate Professor of Clinical Family and Community Medicine University of Missouri Health Care Goals for today
More informationAbuse, Misuse, and Diversion of Prescription Opioids: Evaluating the Problem and Proposed Solutions
Abuse, Misuse, and Diversion of Prescription Opioids: Evaluating the Problem and Proposed Solutions Eric Lavonas, MD, FACEP, FACMT, FAACT Associate Director, Rocky Mountain Poison & Drug Center Denver
More informationPost-Marketing Surveillance: Lessons Learned and Recommendations for the Future
+ Post-Marketing Surveillance: Lessons Learned and Recommendations for the Future Dr. Theodore J. Cicero, PhD Washington University in St. Louis, Department of Psychiatry + Conflicts of Interest/Disclosure
More informationFDA s Response to the Opioid Crisis and the FDA Safe Use Initiative
FDA s Response to the Opioid Crisis and the FDA Safe Use Initiative Scott K. Winiecki, MD Professional Affairs and Stakeholder Engagement Staff (PASES) Center For Drug Evaluation and Research (CDER) U.S.
More informationOpioids drive continued increase in drug overdose deaths
CDC: Drug overdose deaths increase for 11th consecutive year Opioids drive continued increase in drug overdose deaths Atlanta, GA, USA (February 20, 2013) - Drug overdose deaths increased for the 11th
More informationEasy ways to save patients lives: How to prevent, recognize and deter prescription drug abuse.
Easy ways to save patients lives: How to prevent, recognize and deter prescription drug abuse. Chris Stock, PharmD, BCPP Professor (Adjunct), U of U Clinical Pharmacy Specialist, VAMC 1 Attending the presentation
More informationThe Regulatory Agency Will See You Now Kevin L. Zacharoff, MD Disclosures Nothing to Disclose
The Regulatory Agency Will See You Now Kevin L. Zacharoff, MD Disclosures Nothing to Disclose 1 Learning Objectives Identify pain treatment related regulatory agencies Discuss the changing role of regulatory
More informationEvaluating the Impact of Abuse Deterrent Formulations: Methodological Challenges in Postmarketing Data
Evaluating the Impact of Abuse Deterrent Formulations: Methodological Challenges in Postmarketing Data Judy A. Staffa, Ph.D., R.Ph. Associate Director for Public Health Initiatives Office of Surveillance
More informationPennsylvania Prescription Drug Monitoring Program Trends,
DEA Intelligence Report Brief DEA-PHL-DIR-006-17 Pennsylvania Prescription Drug Monitoring Program Trends, 2014-2015 December 2016 1 Executive Summary The abuse and diversion of pharmaceutical drugs, particularly
More informationRisk Reduction Strategies in Pain Management
Risk Reduction Strategies in Pain Management Melissa J. Durham, PharmD, MACM, BCACP, DAAPM Assistant Professor of Clinical Pharmacy USC School of Pharmacy Clinical Pharmacist, The USC Pain Center Learning
More informationPrescription Opioid Dependence and Addiction: Experience in the United States
Prescription Opioid Dependence and Addiction: Experience in the United States September 27, 2013 Richard C. Dart, MD, PhD Director, Rocky Mountain Poison and Drug Center Professor, University of Colorado
More informationThe Role of Dentists in Preventing Opioid Abuse Tufts Health Care Institute Program on Opioid Risk Management 12 th Summit Meeting March 11-12, 2010
The Role of Dentists in Preventing Opioid Abuse Tufts Health Care Institute Program on Opioid Risk Management 12 th Summit Meeting March 11-12, 2010 EXECUTIVE SUMMARY It is well documented in multiple
More informationOpiate Use Disorder and Opiate Overdose
Opiate Use Disorder and Opiate Overdose Irene Ortiz, MD Medical Director Molina Healthcare of New Mexico and South Carolina Clinical Professor University of New Mexico School of Medicine Objectives DSM-5
More informationIn Vitro Considerations for Development Abuse Deterrent Dosage Forms
In Vitro Considerations for Development Abuse Deterrent Dosage Forms Presentation to AAPS Annual Meeting Nov 3, 2014 Nagesh Bandi, Ph.D. Global CMC New Products Pfizer Inc. 1 Disclaimer The thoughts and
More informationT E C H N O L O G Y INTRODUCTION F I G U R E 1 F I G U R E 2
ABUSE DETERRENT T E C H N O L O G Y New Abuse Deterrent Formulation (ADF) Technology for Immediate-Release Opioids By: Johannes Bartholomäus, PhD; Sebastian Schwier, PhD; Martin Brett, Hans-Jürgen Stahlberg,
More informationCDC s Approach to Addressing the Opioid Overdose Epidemic
CDC s Approach to Addressing the Opioid Overdose Epidemic Sarah Bacon National Center for Injury Prevention and Control Division of Unintentional Injury Prevention June 23, 2016 500,000 drug overdose deaths
More informationAbuse of opioid painkillers in the US is a major problem
As appeared in January 2018 Tablets & Capsules www.tabletscapsules.com formulation Abuse-deterrent formulation technologies: Opportunities and limitations Alyn McNaughton Lonza Too many Americans are misusing
More informationResponding to the Prescription Opioid and Heroin Crisis: An Epidemic of Addiction
Responding to the Prescription Opioid and Heroin Crisis: An Epidemic of Addiction Andrew Kolodny, MD Co-Director, Opioid Policy Research Collaborative Institute for Behavioral Health Schneider Institutes
More informationA nation in pain: Focus on Medicaid
DATA INSIGHTS A nation in pain: Focus on Medicaid Opioid pain medications have become one of the most controversial classes of prescription therapy. While they provide great benefits in controlling both
More informationWisconsin Opioid Prescribing Guideline Draft Scope and purpose of the guideline
Wisconsin Opioid Prescribing Guideline Draft Scope and purpose of the guideline: To help providers make informed decisions about acute and chronic pain treatment -pain lasting longer than three months
More informationUnderstanding and Combating the Heroin Epidemic
Understanding and Combating the Heroin Epidemic Kelly Dunn, Ph.D. Assistant Professor; Johns Hopkins School of Medicine Department of Psychiatry and Behavioral Sciences 1 Talk Outline What is causing the
More informationThe Opioid Epidemic and its Cost on Society and the Economy
The Opioid Epidemic and its Cost on Society and the Economy 6 out of 10 In 2014, more people died from drug overdoses than any other year on record with more than six out of ten deaths involving opioids.
More informationAbuse-Deterrent Formulations of Opioids: Effectiveness and Value
Abuse-Deterrent Formulations of Opioids: Effectiveness and Value Evidence Report June 28, 2017 Prepared for: Institute for Clinical and Economic Review, 2017 ICER Staff/Consultants Reiner Banken, MD, MSc
More informationSAFE OPIOID PRESCRIBING C.U.R.E.S. PROGRAM
Sorin Buga, MD Associate Clinical Professor Department of Supportive Care City of Hope National Medical Center SAFE OPIOID PRESCRIBING C.U.R.E.S. PROGRAM Click to edit Master Presentation Date Disclosure
More informationVanila M Singh, MD MACM Chief Medical Officer Office of the Assistant Secretary for Health U.S. Department of Health and Human Services
Vanila M Singh, MD MACM Chief Medical Officer Office of the Assistant Secretary for Health U.S. Department of Health and Human Services 1 Summit Objectives Engage subject matter experts and key federal,
More informationAddressing the Opioid Epidemic in Tennessee
Addressing the Opioid Epidemic in Tennessee A Multidisciplinary Approach Melissa McPheeters, PhD, MPH Director, Informatics and Public Health Analytics 26 108 733 *Source: CDC References Centers for
More informationManaged Care Pushes for Safer Opioid Oversight
Page 1 of 6 Clinical AUGUST 11, 2017 Managed Care Pushes for Safer Opioid Oversight High-risk pain Rx eyed Denver Health systems haven t escaped the nation s ongoing opioid crisis, as evidenced by surging
More informationHigh-Decile Prescribers: All Gain, No Pain?
High-Decile Prescribers: All Gain, No Pain? Len Paulozzi, MD, MPH National Center for Injury Prevention and Control Centers for Disease Control and Prevention National Center for Injury Prevention and
More informationGabapentin diversion and misuse: Data from law enforcement and substance users
Gabapentin diversion and misuse: Data from law enforcement and substance users Mance E. Buttram, PhD NDEWS Presents Webinar 14 March 2018 Objectives 1. Brief overview of gabapentin literature 2. Present
More informationOpioid Use and Other Trends
Opioid Use and Other Trends National Overview Across the nation communities are struggling with a devastating increase in the number of people misusing opioid drugs, leading many to identify the current
More informationASPMN Conference Baltimore, Maryland
ASPMN Conference Baltimore, Maryland Prescribing Controlled Substances Managing Risk and Optimizing Outcomes September 13, 2012 Tracey Fremd, NP Tracey Fremd Consulting, Inc. Most Common Uses for Controlled
More informationTITLE: Tamper-Resistant Oxycodone: A Review of the Clinical Evidence and Costeffectiveness
TITLE: Tamper-Resistant Oxycodone: A Review of the Clinical Evidence and Costeffectiveness DATE: 25 June 2015 CONTEXT AND POLICY ISSUES Oxycodone is a prescription opioid used for chronic and acute pain
More informationPrescription Drug Monitoring Programs and Other State-Level Strategies
Prescription Drug Monitoring Programs and Other State-Level Strategies Interventions to Reduce Opioid-Related Harms: Misuse, Abuse, Addiction, and Overdose Tamara M. Haegerich, PhD Acting Associate Director
More informationDECEMBER 7, 2017 THE OPIOID EPIDEMIC & THE UNIVERSITY S RESPONSE
DECEMBER 7, 2017 THE OPIOID EPIDEMIC & THE UNIVERSITY S RESPONSE Agenda Welcome & Introductions Trending Articles The Opioid Epidemic Key Updates What are Opioids? Chemically similar to heroin, prescribed
More informationOpioid Abuse and the Development of Abuse-Deterrent Drugs: Trends and Coverage in the Medicare Part D Program
Opioid Abuse and the Development of Abuse-Deterrent Drugs: Trends and Coverage in the Medicare Part D Program June 2015 Prepared by: Caroline F. Pearson, Craig Burton, Christine Harhaj, John A. Graziano
More informationOXYCONTIN Diversion & Abuse Drug Enforcement Administration Office of Diversion Control October 2003
OXYCONTIN Diversion & Abuse Office of Diversion Control October 2003 OXYCONTIN OxyContin is a controlled release form of Schedule II oxycodone Manufactured in tablet form and intended for oral ingestion
More informationAVOIDING PHYSICIAN STRESS IN MEDICAL PAIN MANAGEMENT
AVOIDING PHYSICIAN STRESS IN MEDICAL PAIN MANAGEMENT OR HOW TO TREAT PATIENTS AND STAY OUT OF TROUBLE AT THE SAME TIME L AYN E E. SUBERA, D O CONTENTS 1. Perspectives on the opioid situation 2. Oklahoma
More informationMedicare Advantage Outreach and Education Bulletin
Medicare Advantage Outreach and Education Bulletin Blue Cross and Blue Shield of Georgia Prescription Drug Monitoring Programs Prescription drug abuse and diversion are acute problems in the area of pain
More informationThe Future of Prevention: Addressing the Prescription Drug Abuse and the Opioid/Heroin Epidemic in our Country
Integrating Primary and Behavioral Health Care Through the Lens of Prevention July 14, 2016 New Orleans, Louisiana The Future of Prevention: Addressing the Prescription Drug Abuse and the Opioid/Heroin
More informationResponding to the Prescription Opioid and Heroin Crisis: An Epidemic of Addiction
Responding to the Prescription Opioid and Heroin Crisis: An Epidemic of Addiction Andrew Kolodny, M.D.. Executive Director, Physicians for Responsible Opioid Prescribing Senior Scientist, Heller School
More informationTHE PRESCRIPTION OPIOID EPIDEMIC: IN SEARCH OF MISSION CONTROL. G. Caleb Alexander, MD, MS November 11, 2014
THE PRESCRIPTION OPIOID EPIDEMIC: IN SEARCH OF MISSION CONTROL G. Caleb Alexander, MD, MS November 11, 2014 Disclosures and Funding Disclosures Consultant: IMS Health Chair, Food and Drug Administration,
More informationAcademic Medical School: Implementing Curriculum in Chronic Pain and Opioid Misuse. Jill M Williams, MD
Academic Medical School: Implementing Curriculum in Chronic Pain and Opioid Misuse Pain, Pain Management and the Opioid Epidemic Symposium Jill M Williams, MD Professor Psychiatry Director, Division Addiction
More informationSeptember 1, The Honorable Tom Price, MD Secretary Department of Health and Human Services 200 Independence Avenue SW Washington, DC 20201
September 1, 2017 The Honorable Tom Price, MD Secretary Department of Health and Human Services 200 Independence Avenue SW Washington, DC 20201 Dear Secretary Price: The National Association of County
More informationOpioid prescription drug patterns in diagnosed and non-diagnosed opioid use disorder populations
Opioid prescription drug patterns in diagnosed and non-diagnosed opioid use disorder populations Exploring prescription patterns among commercially insured patients with diagnosed opioid use disorder and
More informationThe Prescription Drug Overdose Epidemic
The Prescription Drug Overdose Epidemic Rita Noonan, PhD National Center for Injury Prevention and Control Centers for Disease Control and Prevention National Center for Injury Prevention and Control Division
More informationOHIO S PRESCRIPTION DRUG OVERDOSE EPIDEMIC:
Cuyahoga County Board of Health OHIO S PRESCRIPTION DRUG OVERDOSE EPIDEMIC: NOVEMBER 5, 2014 CONTRIBUTING FACTORS AND ONGOING PREVENTION EFFORTS DEFINITIONS Opiate- originate from naturally-occurring elements
More informationRunning Head: PICOT-D ASSIGNMENT 1. NURS 610: PICOT-D Assignment. Peggie L. Powell. VCU School of Nursing DNP Program
Running Head: PICOT-D ASSIGNMENT 1 NURS 610: PICOT-D Assignment Peggie L. Powell VCU School of Nursing DNP Program PICOT-D ASSIGNMENT 2 PICOT-D Component Component Wording (P)atient population Among providers
More informationRisk Classification Modeling to Combat Opioid Abuse
Risk Classification Modeling to Combat Opioid Abuse Improve Data Sharing to Identify High-Risk Prescribers of Opioids Christopher Sterling Chief Statistician NCI, Inc. www.nciinc.com 11730 Plaza America
More informationStrategies to Manage The Opioid Crisis
Strategies to Manage The Opioid Crisis Matt Feehery, LCDC Senior Vice President & CEO PaRC (Prevention & Recovery Center) Behavioral Health Services February 1, 2018 A Pill for Your Pain But my doctor
More informationPerformance of North Carolina's System for Monitoring Prescription Drug Abuse. Session Law , Section 12F.16.(q)
Performance of North Carolina's System for Monitoring Prescription Drug Abuse Session Law 2015-241, Section 12F.16.(q) Report to the Joint Legislative Oversight Committee on Health and Human Services and
More informationStrategies for Federal Agencies
Confronting Pain Management and the Opioid Epidemic Strategies for Federal Agencies Over the past 25 years, the United States has experienced a dramatic increase in deaths from opioid overdose, opioid
More informationSpotlight on Health Policy Beyond the Clinical: The Opioid Epidemic. October 25, 2017
Spotlight on Health Policy Beyond the Clinical: The Opioid Epidemic October 25, 2017 Disclosures and Disclaimer Neither the Institute for Health Policy and Leadership (IHPL) nor I have any relevant financial
More informationOpioids: What You Should Know About Opioid Prescribing. Denis G. Patterson, DO Nevada State Medical Association October 19, 2016
Opioids: What You Should Know About Opioid Prescribing Denis G. Patterson, DO Nevada State Medical Association October 19, 2016 Contact Information Denis G. Patterson, DO Nevada Advanced Pain Specialists
More informationDocuments Regarding Drug Abuse Assessments
Overview of the FDA Guidance Documents Regarding Drug Abuse Assessments ABUSE DETERRENT FORMULATION SCIENCE MEETING DISCUSSION OF THE FDA DRAFT GUIDANCE FOR INDUSTRY: ABUSE DETERRENT OPIOIDS EVALUATION
More informationSubmitted to the House Energy and Commerce Committee. Federal Efforts to Combat the Opioid Crisis
STATEMENT FOR THE RECORD Submitted to the House Energy and Commerce Committee Federal Efforts to Combat the Opioid Crisis October 25, 2017 America s Health Insurance Plans 601 Pennsylvania Avenue, NW Suite
More informationPrescription Opioid Overdose in Oregon: A public health perspective
Prescription Opioid Overdose in Oregon: A public health perspective Katrina Hedberg, MD, MPH Health Officer & State Epidemiologist Oregon Public Health Division Oregon Health Authority All-Cause Mortality,
More informationThe Opioid Crisis among the Privately Insured
The Opioid Crisis among the Privately Insured The Opioid Abuse Epidemic as Documented in Private Claims Data A FAIR Health White Paper, July 2016 Copyright 2016, FAIR Health, Inc. Summary The United States
More informationPrescription Drug Abuse National Perspective
Prescription Drug Abuse National Perspective Timothy P. Condon, Ph.D. Science Policy Advisor Office of the Director White House Office of National Drug Control Policy Commonly Abused Prescription Drugs
More informationWashington State PMP Data Mapping Project
Washington State PMP Data Mapping Project 2014 Category 3 Grant Harold Rogers Category 3 Grantee Meeting February 25, 2015 Washington State BACKGROUND: OPIOID ISSUES AND PLANNING 2 WA Unintentional Opioid
More informationTake Home Naloxone: Law Update and Considerations for Pharmacy Professionals
Take Home Naloxone: Law Update and Considerations for Pharmacy Professionals Clint Ross, PharmD, BCPP Clinical Pharmacy Specialist Psychiatry Residency Program Director Psychiatric Pharmacy Medical University
More informationGabapentin diversion and misuse in the United States from a law enforcement perspective: Diversion rates and qualitative research findings
Gabapentin diversion and misuse in the United States from a law enforcement perspective: Diversion rates 2002-2015 and qualitative research findings Mance E. Buttram, PhD Steven P. Kurtz, PhD 2 nd European
More information4/3/2018. The Role of Pharmacists in the Safe Prescribing of Opioids: Having the Tough Talks with Patients and Prescribers. Learning Objectives
The Role of Pharmacists in the Safe Prescribing of Opioids: Having the Tough Talks with Patients and Prescribers Melissa Durham Tania Gregorian Vlada Manzur Learning Objectives Describe current issues
More informationLisa Marzilli, PharmD, CDOE TOP 3 REASONS PEOPLE VISIT THEIR DOCTOR
Lisa Marzilli, PharmD, CDOE TOP 3 REASONS PEOPLE VISIT THEIR DOCTOR 1 1. Skin disorders, including cysts, acne, and dermatitis. 2. Joint disorders, including osteoarthritis. 3. Back problems. Source: Mayo
More informationOpioid analgesic therapy in pain management: how we got here from there
National Organization of Alternative Programs March 17, 2016 Opioid analgesic therapy in pain management: how we got here from there Gary M. Reisfield, M.D. Divisions of Addiction Medicine and Forensic
More informationBREAKING THE CYCLE T H E O P I O I D E P I D E M I C I N A M E R I C A
BREAKING THE CYCLE T H E O P I O I D E P I D E M I C I N A M E R I C A OVERVIEW Across the United States, about 90 people die per day due to opioid overdoses, which equates to every three in five overdose
More information6/6/2017. The Role of ADFs in Curbing Opioid Abuse Can ADFs Reduce Opioid Abuse? 12-Month Financial Disclosures* Objectives
The Role of ADFs in Curbing Opioid Abuse Can ADFs Reduce Opioid Abuse? Lynn R. Webster, M.D. Vice President of Scientific Affairs PRA Health Sciences Salt Lake City, UT LRWebsterMD@gmail.com (801) 892-5140
More information